bioRxiv preprint doi: https://doi.org/10.1101/2020.08.03.231340; this version posted August 3, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Neoleukin Therapeutics, USA. 2020.

Title: De novo design of ACE2 protein decoys to neutralize SARS-CoV-2
Authors: â€‹Thomas W. Linsky1,â€‹ Â§, Renan Vergara1,â€‹ Â§, Nuria Codina1,â€‹ Â§, Jorgen W. Nelsâ€‹on1,â€‹ Â§,

Matthew J. Walker1â€‹ , Wen Su2â€‹ , â€‹Tien-Ying Hsiang3â€‹ , Katharina Esser-Nobis3â€‹ , Kevin Yâ€‹u1â€‹ , Yixuan J.
Hou4â€‹ , Tanu Priya1â€‹ , Masaya Mitsumoto1â€‹ , Avery Pong1â€‹ , Uland Y. Lau1â€‹ , Marsha L. Mason1â€‹ , Jerry
Chen1â€‹ , Alex Chen1â€‹ , Tania Berrocal1, Hong Peng1â€‹ , Nicole S. Clairmont1â€‹ , Javier Castellanos1â€‹ ,
Yu-Ru Lin1â€‹ , Anna Josephson-Day1â€‹ , Ralph Baric4â€‹ , Carl D. Walkey1â€‹ , Ryan Swanson1â€‹ , Michael
â€‹ *
Gale Jrâ€‹3, Luis M. Blancas-Mejia1â€‹ , Hui-Ling Yenâ€‹2, and Daniel-Adriano Silva1,

Affiliations:
1.

Neoleukin Therapeutics Inc., Seattle, WA 98102, USA.
School of Public Health, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong
Kong Special Administrative Region, China.
3.
Center for Innate Immunity and Immune Disease, Department of Immunology, University of
Washington, Seattle, WA 98195, USA.
4.
Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC,
USA.
Â§
These authors contributed equally to this work
* Correspondence to:â€‹ dadriano@neoleukin.com
2.

Keywords: De novo; protein design; decoy; antiviral; virus neutralization; hyperstable;
COVID-19; SARS; SARS-CoV-2; SARS-1.

Abstract: â€‹There is an urgent need for the ability to rapidly develop effective
countermeasures for emerging biological threats, such as the severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) that causes the ongoing coronavirus disease
2019 (COVID-19) pandemic. We have developed a generalized computational design
strategy to rapidly engineer â€‹de novo â€‹proteins that precisely recapitulate the protein
surface targeted by biological agents, like viruses, to gain entry into cells. The designed
proteins act as decoys that block cellular entry and aim to be resilient to viral mutational
escape. Using our novel platform, in less than ten weeks, we engineered, validated, and
optimized â€‹de novo protein decoys of human angiotensin-converting enzyme 2 (hACE2),
the membrane-associated protein that SARS-CoV-2 exploits to infect cells. Our
optimized designs are hyperstable â€‹de novo proteins (~18-37 kDa), have high affinity for
the SARS-CoV-2 receptor binding domain (RBD) and can potently inhibit the virus
infection and replication in vitâ€‹ro. Future refinements to our strategy can enable the rapid
development of other therapeutic â€‹de novo protein decoys, not limited to neutralizing
viruses, but to combat any agent that explicitly interacts with cell surface proteins to
cause disease.

1

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.03.231340; this version posted August 3, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Neoleukin Therapeutics, USA. 2020.

Main Text: Since its emergence in December of 2019, SARS-CoV-2 has caused
millions of cases of COVID-19 and become a global pandemic. The need for effective
strategies to prevent and treat the disease remains unfulfilled and urgent â€‹(â€‹1â€‹)â€‹. There are
multiple ongoing efforts to develop prophylactics and therapeutics using several
approaches â€‹(â€‹2â€‹) such as vaccination â€‹(â€‹3â€‹)â€‹, protein engineering â€‹(â€‹1â€‹) and small molecule drug
discovery â€‹(â€‹4â€‹)â€‹. The high mutational rate of positive sense single-strand RNA (+ssRNA)
viruses â€‹(â€‹5â€‹â€“â€‹7â€‹) can lead to viral escape â€‹(â€‹8â€‹)â€‹, which could rapidly compromise the efficacy
of many treatments under development, possibly leading to recurrent outbreaks of
SARS-CoV-2 with globally catastrophic consequences. Mutations have already
spontaneously occurred in the spike (S) protein of SARS-CoV-2 â€‹(â€‹9â€‹)â€‹, and some of them
are already suspected to increase the infectivity of the virus â€‹(â€‹10â€‹)â€‹). Deep mutational
scanning studies have further shown that there are mutations that can enable the virus
to escape known neutralizing antibodies, as well as mutations that can increase its
binding affinity for hACE2 â€‹(â€‹11â€‹, â€‹12â€‹)â€‹. A pressing need exists to develop novel therapeutics
that can be more resistant to viral mutation and immunologic escape by SARS-CoV-2.
Traditional approaches to combat viruses (e.g. monoclonal antibodies) ultimately rely on
molecules interacting with viruses in a way that is fundamentally different than how the
virus engages with its cellular targets â€‹(â€‹13â€‹, â€‹14â€‹)â€‹. Viruses can exploit such structural
discrepancy to evade neutralization, changing the shape of their proteins to prevent
recognition by the neutralizing agents while preserving their viral function. To address
these challenges, we have developed a general protein design strategy that enables the
rapid and accurate computational design of â€‹de novo proteins that neutralize a virus by
disabling its mechanism of cellular entry. â€‹By mimicking the exact protein surface that the
virus targets on its first contact with the cellâ€™s membrane, our â€‹de novo designer proteins
can outcompete the viral interaction and act as neutralizing agents. Since a de novo
protein decoy mirrors the natural viral cellâ€™s protein target, mutations that affect (e.g.
weaken) the interaction of the virus with the â€‹de novo decoy are likely to have a similar
effect on its interaction with the cell, automatically conferring the designed decoys with
resiliency to mutational viral escape.
SARS-CoV-2 invades host cells in a two-step process â€‹(â€‹15â€‹â€“â€‹17â€‹)â€‹. The first step occurs
when the SARS-CoV-2 S protein attaches to the cell via binding to the angiotensin
converting enzyme 2 (ACE2), triggering endocytosis and the second when it escapes
the endosome via a protease-cleavage-mediated fusion peptide â€‹(â€‹18â€‹)â€‹. The process is
similar to the beta-coronaviruses HCoV-NL63 and SARS-CoV-1, which also target
ACE2 for cellular entry â€‹(â€‹19â€‹)â€‹. In principle, inhibiting the viral interaction with ACE2 should
therefore prevent infection. â€‹In a span of ten weeâ€‹ks (figure 1J), we applieâ€‹d our design
strategy to engineer, validate and optimize â€‹de novo protein decoys of human ACE2
(hACE2) to neutralize â€‹SARS-CoV-2 â€‹(figure S1)â€‹. Our best optimized design, CTC-445.2d
(ConquerTheCorona445.2duo), is a thermodynamically hyperstable, bi-valent,
single-chain protein that exhibits low nanomolar affinity for the RBD of SARS-CoV-2 and
is cross-reactive with SARS-CoV-1. As predicted, the strong and specific binding of
2

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.03.231340; this version posted August 3, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Neoleukin Therapeutics, USA. 2020.

CTC-445.2d to the RBD of SARS-CoV-2 translated into potent and specific â€‹in vitro viral
neutralization. As expected, the effect SARS-CoV-2 RBD mutations in binding are
closely mirrored between hACE2 and the de novo decoys. â€‹At a size of ~160 a.a. and
combining multiple É‘-helical and Î²-strand structures, CTC-445 and its optimized variants
are among the most advanced examples of â€‹de novo therapeutic proteins reported to
date.
Computational design and optimization of de novo ACE2 decoys to neutralize
SARS-CoV-2. We started the design process of the de novo decoys by identifying the
hACE2 structural motifs that form the protein surface that SARS-CoV-2 binds to gain
entry into the cell. We based our effort on three publicly available structures of hACE2 in
complex with the RBDs of SARS-CoV-1 (PDB: 6CS2) and SARS-CoV-2 (PDBs: 6VW1,
6M17) â€‹(â€‹20â€‹â€“â€‹22â€‹)â€‹. By visual inspection, we identified four discontiguous hACE2 structural
elements that form the target protein binding interface. We selected the major three of
these elements to build our de novo decoys: two long alpha helices (H1 and H2) and a
short beta hairpin (EE3) (figures 1A and S2). To generate molecules that are
biologically inert for humans, our design strategy avoided incorporating elements of
hACE2 that are known (or predicted) to be biologically active, such as its catalytic site
and/or its interface with the cell. We built new disembodied â€‹de novo secondary structure
elements tailored to support the target structural elements in a way that is both
compatible with globular folding and that stabilizes the binding interface (figure 1B and
methods), inspired by recent developments in the design of de novo structural elements
(â€‹23â€‹â€“â€‹26â€‹)â€‹. Then, in a spirit similar to the design of Neoleukin-2/15 (Neo-2/15) â€‹(â€‹23â€‹, â€‹27â€‹)â€‹, we
used a combinatorial approach based on Rosettaâ€™s "protein_mimic_designer" to
generate multiple fully-connected protein topologies that contain all the desired
structural and binding elements â€‹(â€‹23â€‹)â€‹. The design of the protein decoys was constrained
to fully preserve --intact up to each amino acid's conformation-- the target binding
interface (figure 1A-B, 2A-B), such as the designed de novo decoys can be more
resilient to mutational escape by the virus. We then used Rosetta to generate de novo
amino acid sequences predicted to fold into the target structures (figure 1B and
methods), and evaluated the designs with an automatic filtering pipeline based on nine
computational parameters, including predictions of smooth folding funnels into stable
protein structures (figure 1C-D). The top ranking designs (see methods) were selected
for experimental testing of binding to SARS-CoV-2 RBD (figure 1E).
We engineered ~35,000 plausible computational models of â€‹de novo ACE2 decoys, and
by using yeast display, we individually tested 196 of the top ranked designs for
SARS-CoV-2 binding. Out-of-the-box, one of the designs, CTC-445, showed
strong/nanomolar specific binding to the SARS-CoV-2 RBD (figure 1E, S3, and
methods). Despite its high affinity, recombinantly expressed CTC-445 was a weak (ÂµM
range) competitor of hACE2 binding to SARS-CoV-2 RBD (figure 1I). A single round of
directed evolution and rational combination of the most frequently observed (stabilizing
and affinity-improving) mutations led to CTC-445.2, which contains five amino acid
3

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.03.231340; this version posted August 3, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Neoleukin Therapeutics, USA. 2020.

substitutions (figure 1G, S4, S5, and table S1, see methods). The improving mutations
play a role in optimizing the stability of the proteinâ€™s native state, and none of them is at
the binding interface (figures 2C-D, S4, and methods). CTC-445.2 is highly soluble,
monodisperse (figure 1H and S7), thermodynamically hyperstable (figure 2C-D), a
strong competitor of SARS-CoV-2 RBD binding to hACE2 (figure 1I), and a potent in
vitro inhibitor of SARS-CoV-2 cell infection (figure 3). A simple domain duplication of
CTC-445.2 (figure 2B) allowed us to further develop CTC-445.2d, which has similar
favorable biochemical characteristics, but due to its bivalent nature exhibits a ~100-fold
improved SARS-CoV-2 neutralizing potency.
Biophysical and biochemical properties of the de novo protein ACE2 decoys.
CTC-445 is a 160 a.a. protein comprising 18 of the natural amino acids (it does not
contain cysteine or tryptophan residues), has nanomolar affinity for the RBD of
SARS-CoV-2 (Kâ€‹d = 357 nM, see table S2 and methods) and can outcompete binding of
the SARS-CoV-2 RBD to hACE2 (ICâ€‹50 = 1675 nM, figure 1I). Notably, CTC-445 exhibits
lower binding potency for SARS-CoV-2 than hACE2 (Kâ€‹d â€‹= 4.6 nM, ICâ€‹50 = 10.9 nM, table
S3) and a very weak cross reactivity to SARS-CoV-1 (Kâ€‹d â‰ˆ 55 ÂµM, figure 2F, table S2
and methods). We believe that the low binding affinity observed is likely due to the low
stability of its folded state (Î”Gâ€‹NIâ€‹~ -2.7 kcal molâ€‹-1â€‹, Tâ€‹mâ€‹~ 75.3 Â°C, figure 1F and 2C-E). â€‹In
contrast, the experimentally stability-optimized de novo decoy CTC-445.2 is
predominantly monomeric (figure 1H and S7), thermodynamically hyperstable (Î”Gâ€‹NIâ€‹~
-5.0 kcal molâ€‹-1â€‹, Tâ€‹m ~ 93 â„ƒ, figure 2C-D), exhibits low nanomolar affinity for the RBD of
SARS-CoV-2 (Kâ€‹d â€‹~ 21.0 nM, see table S3), and has improved cross-reactivity to
SARS-CoV-1 (Kâ€‹d ~ 7.1 ÂµM, table S2 and figure 2F). CTC-445.2 is capable of
outcompeting hACE2 binding to the SARS-CoV-2 RBD at low nanomolar concentrations
(ICâ€‹50 ~ 10.4 nM, figure 1I). Single-site sâ€‹aturation mutagenesis (SSM) â€‹(â€‹28â€‹, â€‹29â€‹) of the
SARS-CoV-2 RBD binding interface showed that the effects of mutations in the binding
of hACE2 are closely recapitulated by CTC-445.2 (see figure S14). â€‹The bivalent de
novo protein decoy CTC-445.2d is our top optimized variant due to its remarkable
binding and neutralizing potency, albeit it has a slightly less stable native state than its
parent (Î”Gâ€‹NI ~ -4.5, Tâ€‹m ~ 71.7 â„ƒ; figure 2C-D) highlighting perhaps the advantage of
starting with a very stable molecule before attempting a domain duplication to augment
binding potency. The increased avidity of CTC-445.2d confers a ~10-fold improvement
in binding affinity of the de novo decoy for both SARS-CoV-2 RBD (Kâ€‹d ~ 3.5 nM, table
S2) and SARS-CoV-1 RBD (Kâ€‹d ~ 587 nM, table S2 and figure S9), as well as a similar
increase in its ability to outcompete hACE2 binding to the SARS-CoV-2 RBD (ICâ€‹50 ~ 0.7
nM, figure 1I).
Functional characterization of CTC-445.2 and CTC-445.2d. Tâ€‹he strong binding of our
optimized â€‹de novo protein decoys to the SARS-CoV-2 RBD translated into effective and
specific â€‹in vitro neutralization of viral cell infection (figure 3). The presence of the â€‹de
novo decoys showed no impact on mammalian cell viability. Co-incubation of hACE2
with the decoys had no impact on the enzymatic activity of hACE2 (figure 3E)â€‹. Both of
4

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.03.231340; this version posted August 3, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Neoleukin Therapeutics, USA. 2020.

the â€‹de novo hACE2 decoys were able to fully neutralize viral infection in three different
in vitro systems (figure 3A-C). Briefly, in a VSV pseudovirus system expressing the
SARS-CoV-2 spike protein, the â€‹de novo decoys specifically protected HEK 293T cells
overexpressing hACE2 from infection (figure 3A and figure S11). Our â€‹de novo protein
decoys also prevented infection by SARS-CoV-2 expressing the nanoLuc reporter
(SARS-CoV-2 nanoLuc, see methods) in the lung epithelial cell line Calu-3, which
expresses both ACE2 and the transmembrane protease serine 2 (TMPRSS2), known to
augment the infectivity of SARS-CoV-2 â€‹(â€‹30â€‹, â€‹31â€‹) (figure 3B; ECâ€‹50 < 5 nM at MOI=1.0). To
confirm the mechanism of inhibition (i.e. extracellular neutralization of the virus) by
CTC-445.2 and CTC-445.2d, a time-of-addition assay was performed in Vero E6 cells.
Briefly, CTC-445.2 or CTC-445.2d were added either during the full course of infection
(i.e. co-incubated with the virus and in the cell media), before infection (i.e. only
co-incubated with the virus), or after infection (i.e. only in the cell media). As expected,
CTC-445.2 and CTC-445.2d were most effective when continuously present throughout
the full course of infection (figure 3C and S12). To define the activity of CTC-445.2d as
a locally delivered therapeutic to possibly protect the airway from infection, we delivered
a high dose (100 Âµg) of CTC-445.2d to Balb/c mice via inhalation of intranasal droplets.
We observed persistence of fully functional CTC-445.2d in the lungs for more than 24
hours (figure 3D). We also detected CTC-445.2d in blood, raising the possibility that
inhaled therapy might lead to some level of systemic exposure.
Conclusions: The emergence of SARS-CoV-2 as a global health threat has highlighted
the need for the rapid development of novel countermeasures. Soluble â€œdecoyâ€ proteins
are orthogonal to traditional therapeutic approaches such as vaccination, neutralizing
antibodies, or small molecule inhibitors, and might have the potential to better overcome
the problem of mutational viral evasion. Utilizing natural proteins as therapeutics often
presents a number of significant challenges, such as poor stability that can complicate
manufacturing, transport and storage, side effects that can arise from residual/unwanted
biological activity, and the fact that human proteins repurposed as therapeutics pose the
risk of eliciting an autoimmune response with possibly lifelong consequences â€‹(â€‹32â€‹â€“â€‹41)â€‹ â€‹.
Designed â€‹de novo protein decoys offer an avenue to overcome these challenges.
Bâ€‹ecause CTC-445.2d differs in sequence and structure from any natural protein, it
reduces the potential risk of eliciting an autoimmune reaction. The optimized â€‹de novo
protein decoys are easy to manufacture in traditional bacterial systems, and their
thermodynamic hyperstability and full thermal reversibility make them ideal candidates
for transport, storage, and local delivery. Also, due to their remarkable thermodynamic
stability, there is further potential to fine tune de novo protein decoys â€‹(â€‹42â€‹)â€‹. For example,
we have shown that â€‹by simply increasing the avidity of CTC-445.2 it is possible to
greatly augment its potency. As well, we demonstrate that it is also possible to further
increase stability while preserving the function of the de novo decoy (â€‹figure S13â€‹)â€‹. This
tunability could be difficult to achieve with a natural protein such as hACE2, which is
5

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.03.231340; this version posted August 3, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Neoleukin Therapeutics, USA. 2020.

much larger (~90 kDa) and has significantly lower stability (figure S8)â€‹. â€‹The protein
surface that CTC-445 (and its optimized variants) present to â€‹SARS-CoV-2 is designed
to be virtually identical to the natural binding surface that the virus targets in hACE2.
Therefore, mutations in the RBD that affect binding to our de novo decoy are likely to
have a similar effect on the virus' binding to hACE2, effectively making the decoys
functionally resilient to mutational escape (figure S10 and S14). Our principle is also
exemplified by the cross reactivity of our de novo decoys with SARS-CoV-1 despite (at
least) 17 mutations that separate their binding interfaces (figure S9), including a drastic
loop remodeling in the RBDâ€™s ridge region â€‹(â€‹43)â€‹ â€‹.
We have laid the groundwork for a generalized strategy that has the potential to quickly
address emerging biological threats. Our strategy is novel, precise, and fast.
CTC-445.2d is, to our knowledge, the first reported example of a â€‹de novo protein
therapeutic that has been conceptualized, engineered, and validated in less than ten
weeks, matching the rapid speed with which the SARS-CoV-2 threat has emerged.
Moreover, further speed and accuracy improvements to our strategy are theoretically
possible (figure 1G). We envision that future embodiments of our â€‹de novo protein
design paradigm will be generally useful for the rapid development of therapeutic
decoys to treat disease, not only for viral agents, but for any case where interrupting
protein-protein interactions could be beneficial. Combined prowess in structural biology
and â€‹de novo protein design are quickly bringing us to the point where therapeutic
molecules can be engineered on demand.
References and Notes:
1.

D. E. Gordon, G. M. Jang, M. Bouhaddou, J. Xu, K. Obernier, K. M. White, M. J. Oâ€™Meara, V. V. Rezelj, J. Z. Guo, D. L.
Swaney, T. A. Tummino, R. Huettenhain, R. M. Kaake, A. L. Richards, B. Tutuncuoglu, H. Foussard, J. Batra, K. Haas, M.
Modak, M. Kim, P. Haas, B. J. Polacco, H. Braberg, J. M. Fabius, M. Eckhardt, M. Soucheray, M. J. Bennett, M. Cakir, M. J.
McGregor, Q. Li, B. Meyer, F. Roesch, T. Vallet, A. Mac Kain, L. Miorin, E. Moreno, Z. Z. C. Naing, Y. Zhou, S. Peng, Y. Shi, Z.
Zhang, W. Shen, I. T. Kirby, J. E. Melnyk, J. S. Chorba, K. Lou, S. A. Dai, I. Barrio-Hernandez, D. Memon, C.
Hernandez-Armenta, J. Lyu, C. J. P. Mathy, T. Perica, K. B. Pilla, S. J. Ganesan, D. J. Saltzberg, R. Rakesh, X. Liu, S. B.
Rosenthal, L. Calviello, S. Venkataramanan, J. Liboy-Lugo, Y. Lin, X.-P. Huang, Y. Liu, S. A. Wankowicz, M. Bohn, M. Safari, F.
S. Ugur, C. Koh, N. S. Savar, Q. D. Tran, D. Shengjuler, S. J. Fletcher, M. C. Oâ€™Neal, Y. Cai, J. C. J. Chang, D. J. Broadhurst,
S. Klippsten, P. P. Sharp, N. A. Wenzell, D. Kuzuoglu, H.-Y. Wang, R. Trenker, J. M. Young, D. A. Cavero, J. Hiatt, T. L. Roth,
U. Rathore, A. Subramanian, J. Noack, M. Hubert, R. M. Stroud, A. D. Frankel, O. S. Rosenberg, K. A. Verba, D. A. Agard, M.
Ott, M. Emerman, N. Jura, M. von Zastrow, E. Verdin, A. Ashworth, O. Schwartz, C. dâ€™Enfert, S. Mukherjee, M. Jacobson, H. S.
Malik, D. G. Fujimori, T. Ideker, C. S. Craik, S. N. Floor, J. S. Fraser, J. D. Gross, A. Sali, B. L. Roth, D. Ruggero, J. Taunton, T.
Kortemme, P. Beltrao, M. Vignuzzi, A. GarcÃ­a-Sastre, K. M. Shokat, B. K. Shoichet, N. J. Krogan, A SARS-CoV-2 protein
interaction map reveals targets for drug repurposing. Nature (2020), doi:10.1038/s41586-020-2286-9.
2. C. Liu, Q. Zhou, Y. Li, L. V. Garner, S. P. Watkins, L. J. Carter, J. Smoot, A. C. Gregg, A. D. Daniels, S. Jervey, D. Albaiu,
Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases.
ACS Cent Sci.â€‹ â€‹6, 315â€“331 (2020).
3. W.-H. Chen, U. Strych, P. J. Hotez, M. E. Bottazzi, The SARS-CoV-2 Vaccine Pipeline: an Overview. Curr Trop Med Rep, 1â€“4
(2020).
4. L. Zhang, D. Lin, X. Sun, U. Curth, C. Drosten, L. Sauerhering, S. Becker, K. Rox, R. Hilgenfeld, Crystal structure of
SARS-CoV-2 main protease provides a basis for design of improved Î±-ketoamide inhibitors. â€‹Science.â€‹ â€‹368, 409â€“412 (2020).
5. E. C. Smith, M. R. Denison, Coronaviruses as DNA wannabes: a new model for the regulation of RNA virus replication fidelity.
PLoS Pathog.â€‹ â€‹9, e1003760 (2013).
6. S. Duffy, Why are RNA virus mutation rates so damn high? â€‹PLoS Biol.â€‹ â€‹16 (2018), p. e3000003.
7. Z. Zhao, H. Li, X. Wu, Y. Zhong, K. Zhang, Y.-P. Zhang, E. Boerwinkle, Y.-X. Fu, Moderate mutation rate in the SARS
coronavirus genome and its implications. BMC Evol. Biol. 4, 21 (2004).
8. M. B. Doud, S. E. Hensley, J. D. Bloom, Complete mapping of viral escape from neutralizing antibodies. â€‹PLoS Pathog. â€‹ â€‹13,
e1006271 (2017).
9. T. Phan, Genetic diversity and evolution of SARS-CoV-2. â€‹Infect. Genet. Evol. â€‹ â€‹81, 104260 (2020).
10. J. Hu, C.-L. He, Q.-Z. Gao, G.-J. Zhang, X.-X. Cao, Q.-X. Long, H.-J. Deng, L.-Y. Huang, J. Chen, K. Wang, N. Tang, A.-L.
Huang, D614G mutation of SARS-CoV-2 spike protein enhances viral infectivity. â€‹Microbiologyâ€‹ (2020), p. 1620.

6

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.03.231340; this version posted August 3, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Neoleukin Therapeutics, USA. 2020.
11. A. Baum, B. O. Fulton, E. Wloga, R. Copin, K. E. Pascal, V. Russo, S. Giordano, K. Lanza, N. Negron, M. Ni, Y. Wei, G. S.
Atwal, A. J. Murphy, N. Stahl, G. D. Yancopoulos, C. A. Kyratsous, Antibody cocktail to SARS-CoV-2 spike protein prevents
rapid mutational escape seen with individual antibodies. â€‹Scienceâ€‹ (2020), doi:â€‹10.1126/science.abd0831â€‹.
12. T. N. Starr, A. J. Greaney, S. K. Hilton, K. H. D. Crawford, M. J. Navarro, J. E. Bowen, M. A. Tortorici, A. C. Walls, D. Veesler, J.
D. Bloom, Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding.
bioRxivâ€‹ (2020), doi:â€‹10.1101/2020.06.17.157982â€‹.
13. J. ter Meulen, E. N. van den Brink, L. L. M. Poon, W. E. Marissen, C. S. W. Leung, F. Cox, C. Y. Cheung, A. Q. Bakker, J. A.
Bogaards, E. van Deventer, W. Preiser, H. W. Doerr, V. T. Chow, J. de Kruif, J. S. M. Peiris, J. Goudsmit, Human monoclonal
antibody combination against SARS coronavirus: synergy and coverage of escape mutants. â€‹PLoS Med.â€‹ â€‹3, e237 (2006).
14. L. Enjuanes, S. ZuÃ±iga, C. Castano-Rodriguez, J. Gutierrez-Alvarez, J. Canton, I. Sola, in â€‹Advances in virus research â€‹ (Elsevier,
2016; â€‹https://www.sciencedirect.com/science/article/pii/S0065352716300422â€‹), vol. 96, pp. 245â€“286.
15. S. Belouzard, V. C. Chu, G. R. Whittaker, Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage
at two distinct sites. â€‹Proc. Natl. Acad. Sci. U. S. A.â€‹ â€‹106, 5871â€“5876 (2009).
16. J. Shang, Y. Wan, C. Luo, G. Ye, Q. Geng, A. Auerbach, F. Li, Cell entry mechanisms of SARS-CoV-2. â€‹Proc. Natl. Acad. Sci. U.
S. A.â€‹ â€‹117, 11727â€“11734 (2020).
17. J. K. Millet, G. R. Whittaker, Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated
activation of the spike protein. â€‹Proc. Natl. Acad. Sci. U. S. A.â€‹ â€‹111, 15214â€“15219 (2014).
18. X. Ou, Y. Liu, X. Lei, P. Li, D. Mi, L. Ren, L. Guo, R. Guo, T. Chen, J. Hu, Z. Xiang, Z. Mu, X. Chen, J. Chen, K. Hu, Q. Jin, J.
Wang, Z. Qian, Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with
SARS-CoV. Nat. Commun. 11, 1620 (2020).
19. Z. Song, Y. Xu, L. Bao, L. Zhang, P. Yu, Y. Qu, H. Zhu, W. Zhao, Y. Han, C. Qin, From SARS to MERS, Thrusting
Coronaviruses into the Spotlight. â€‹Virusesâ€‹. â€‹11 (2019), doi:â€‹10.3390/v11010059â€‹.
20. R. Yan, Y. Zhang, Y. Li, L. Xia, Y. Guo, Q. Zhou, Structural basis for the recognition of SARS-CoV-2 by full-length human
ACE2. Science. 367, 1444â€“1448 (2020).
21. Q. Wang, Y. Zhang, L. Wu, S. Niu, C. Song, Z. Zhang, G. Lu, C. Qiao, Y. Hu, K.-Y. Yuen, Q. Wang, H. Zhou, J. Yan, J. Qi,
Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2. â€‹Cellâ€‹. â€‹181, 894â€“904.e9 (2020).
22. J. Lan, J. Ge, J. Yu, S. Shan, H. Zhou, S. Fan, Q. Zhang, X. Shi, Q. Wang, L. Zhang, X. Wang, Structure of the SARS-CoV-2
spike receptor-binding domain bound to the ACE2 receptor. Nature. 581 (2020), pp. 215â€“220.
23. D.-A. Silva, S. Yu, U. Y. Ulge, J. B. Spangler, K. M. Jude, C. LabÃ£o-Almeida, L. R. Ali, A. Quijano-Rubio, M. Ruterbusch, I.
Leung, Others, De novo design of potent and selective mimics of IL-2 and IL-15. â€‹Natureâ€‹. â€‹565, 186â€“191 (2019).
24. F. Sesterhenn, C. Yang, J. Bonet, J. T. Cramer, X. Wen, Y. Wang, C.-I. Chiang, L. A. Abriata, I. Kucharska, G. Castoro, S. S.
Vollers, M. Galloux, E. Dheilly, S. Rosset, P. CorthÃ©sy, S. Georgeon, M. Villard, C.-A. Richard, D. Descamps, T. Delgado, E.
Oricchio, M.-A. Rameix-Welti, V. MÃ¡s, S. Ervin, J.-F. ElÃ©ouÃ«t, S. Riffault, J. T. Bates, J.-P. Julien, Y. Li, T. Jardetzky, T. Krey, B.
E. Correia, De novo protein design enables the precise induction of RSV-neutralizing antibodies. â€‹Science â€‹. â€‹368 (2020),
doi:â€‹10.1126/science.aay5051â€‹.
25. J. Zhou, A. E. Panaitiu, G. Grigoryan, A general-purpose protein design framework based on mining sequence-structure
relationships in known protein structures. â€‹Proc. Natl. Acad. Sci. U. S. A.â€‹ â€‹117, 1059â€“1068 (2020).
26. D.-A. Silva, B. E. Correia, E. Procko, in â€‹Computational Design of Ligand Binding Proteins â€‹, B. L. Stoddard, Ed. (Springer New
York, New York, NY, 2016; â€‹https://doi.org/10.1007/978-1-4939-3569-7_17â€‹), pp. 285â€“304.
27. A. Quijano-Rubio, U. Y. Ulge, C. D. Walkey, D.-A. Silva, The advent of de novo proteins for cancer immunotherapy. Curr. Opin.
Chem. Biol.â€‹ â€‹56, 119â€“128 (2020).
28. A. Chevalier, D.-A. Silva, G. J. Rocklin, D. R. Hicks, R. Vergara, P. Murapa, S. M. Bernard, L. Zhang, K.-H. Lam, G. Yao, C. D.
Bahl, S.-I. Miyashita, I. Goreshnik, J. T. Fuller, M. T. Koday, C. M. Jenkins, T. Colvin, L. Carter, A. Bohn, C. M. Bryan, D. A.
FernÃ¡ndez-Velasco, L. Stewart, M. Dong, X. Huang, R. Jin, I. A. Wilson, D. H. Fuller, D. Baker, Massively parallel de novo
protein design for targeted therapeutics. â€‹Natureâ€‹. â€‹550, 74â€“79 (2017).
29. T. A. Whitehead, A. Chevalier, Y. Song, C. Dreyfus, S. J. Fleishman, C. De Mattos, C. A. Myers, H. Kamisetty, P. Blair, I. A.
Wilson, D. Baker, Optimization of affinity, specificity and function of designed influenza inhibitors using deep sequencing. â€‹Nat.
Biotechnol. 30, 543â€“548 (2012).
30. M. Hoffmann, H. Kleine-Weber, S. Schroeder, N. KrÃ¼ger, T. Herrler, S. Erichsen, T. S. Schiergens, G. Herrler, N.-H. Wu, A.
Nitsche, M. A. MÃ¼ller, C. Drosten, S. PÃ¶hlmann, SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a
Clinically Proven Protease Inhibitor. â€‹Cell.â€‹ â€‹181, 271â€“280.e8 (2020).
31. W. Sungnak, N. Huang, C. BÃ©cavin, M. Berg, R. Queen, M. Litvinukova, C. Talavera-LÃ³pez, H. Maatz, D. Reichart, F.
Sampaziotis, K. B. Worlock, M. Yoshida, J. L. Barnes, HCA Lung Biological Network, SARS-CoV-2 entry factors are highly
expressed in nasal epithelial cells together with innate immune genes. â€‹Nat. Med.â€‹ â€‹26, 681â€“687 (2020).
32. M. P. Baker, H. M. Reynolds, B. Lumicisi, C. J. Bryson, Immunogenicity of protein therapeutics: The key causes, consequences
and challenges. Self Nonself. 1, 314â€“322 (2010).
33. N. Casadevall, J. Nataf, B. Viron, A. Kolta, J.-J. Kiladjian, P. Martin-Dupont, P. Michaud, T. Papo, V. Ugo, I. Teyssandier, B.
Varet, P. Mayeux, Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. â€‹N.
Engl. J. Med.â€‹ â€‹346, 469â€“475 (2002).
34. M. G. Tovey, C. Lallemand, Immunogenicity and other problems associated with the use of biopharmaceuticals. Ther Adv Drug
Saf.â€‹ â€‹2, 113â€“128 (2011).
35. J. Li, C. Yang, Y. Xia, A. Bertino, J. Glaspy, M. Roberts, D. J. Kuter, Thrombocytopenia caused by the development of
antibodies to thrombopoietin. â€‹Bloodâ€‹. â€‹98, 3241â€“3248 (2001).
36. M. P. Ettinger, T. W. Littlejohn, S. L. Schwartz, S. R. Weiss, H. H. McIlwain, S. B. Heymsfield, G. A. Bray, W. G. Roberts, E. R.
Heyman, N. Stambler, S. Heshka, C. Vicary, H.-P. Guler, Recombinant variant of ciliary neurotrophic factor for weight loss in
obese adults: a randomized, dose-ranging study. â€‹JAMAâ€‹. â€‹289, 1826â€“1832 (2003).
37. M. Findeisen, T. L. Allen, D. C. Henstridge, H. Kammoun, A. E. Brandon, L. L. Baggio, K. I. Watt, M. Pal, L. Cron, E. Estevez, C.
Yang, G. M. Kowalski, L. Oâ€™Reilly, C. Egan, E. Sun, L. M. Thai, G. Krippner, T. E. Adams, R. S. Lee, J. GrÃ¶tzinger, C. Garbers,
S. Risis, M. J. Kraakman, N. A. Mellet, J. Sligar, E. T. Kimber, R. L. Young, M. A. Cowley, C. R. Bruce, P. J. Meikle, P. A.
Baldock, P. Gregorevic, T. J. Biden, G. J. Cooney, D. J. Keating, D. J. Drucker, S. Rose-John, M. A. Febbraio, Treatment of

7

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.03.231340; this version posted August 3, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Neoleukin Therapeutics, USA. 2020.
38.
39.
40.
41.
42.
43.
44.

45.
46.

47.
48.

49.

50.

type 2 diabetes with the designer cytokine IC7Fc. â€‹Nature.â€‹ â€‹574, 63â€“68 (2019).
G. Gao, C. Lebherz, D. J. Weiner, R. Grant, R. Calcedo, B. McCullough, A. Bagg, Y. Zhang, J. M. Wilson, Erythropoietin gene
therapy leads to autoimmune anemia in macaques. â€‹Blood.â€‹ â€‹103, 3300â€“3302 (2004).
H. Schellekens, N. Casadevall, Immunogenicity of recombinant human proteins: causes and consequences. J. Neurol. 251
Suppl 2, II4â€“9 (2004).
I. Mukovozov, T. Sabljic, G. Hortelano, F. A. Ofosu, Factors that contribute to the immmunogenicity of therapeutic recombinant
human proteins. â€‹Thromb. Haemost.â€‹ â€‹99, 874â€“882 (2008).
M. Sauerborn, V. Brinks, W. Jiskoot, H. Schellekens, Immunological mechanism underlying the immune response to
recombinant human protein therapeutics. â€‹Trends Pharmacol. Sci.â€‹ â€‹31, 53â€“59 (2010).
D. Silva, L. Stewart, K. Lam, R. Jin, D. Baker, Structures and disulfide cross-linking of de novo designed therapeutic
mini-proteins. â€‹FEBS J.â€‹ â€‹285, 1783â€“1785 (2018).
J. Shang, G. Ye, K. Shi, Y. Wan, C. Luo, H. Aihara, Q. Geng, A. Auerbach, F. Li, Structural basis of receptor recognition by
SARS-CoV-2. â€‹Nature.â€‹ â€‹581, 221â€“224 (2020).
E. Marcos, B. Basanta, T. M. Chidyausiku, Y. Tang, G. Oberdorfer, G. Liu, G. V. T. Swapna, R. Guan, D.-A. Silva, J. Dou, J. H.
Pereira, R. Xiao, B. Sankaran, P. H. Zwart, G. T. Montelione, D. Baker, Principles for designing proteins with cavities formed by
curved Î² sheets. Science. 355, 201â€“206 (2017).
D. G. Gibson, L. Young, R.-Y. Chuang, J. C. Venter, C. A. Hutchison 3rd, H. O. Smith, Enzymatic assembly of DNA molecules
up to several hundred kilobases. â€‹Nat. Methods.â€‹ â€‹6, 343â€“345 (2009).
E.-M. Strauch, S. M. Bernard, D. La, A. J. Bohn, P. S. Lee, C. E. Anderson, T. Nieusma, C. A. Holstein, N. K. Garcia, K. A.
Hooper, R. Ravichandran, J. W. Nelson, W. Sheffler, J. D. Bloom, K. K. Lee, A. B. Ward, P. Yager, D. H. Fuller, I. A. Wilson, D.
Baker, Computational design of trimeric influenza-neutralizing proteins targeting the hemagglutinin receptor binding site. â€‹Nat.
Biotechnol.â€‹ â€‹35, 667â€“671 (2017).
L. Benatuil, J. M. Perez, J. Belk, C.-M. Hsieh, An improved yeast transformation method for the generation of very large human
antibody libraries. Protein Eng. Des. Sel. 23, 155â€“159 (2010).
M. T. Koday, J. Nelson, A. Chevalier, M. Koday, H. Kalinoski, L. Stewart, L. Carter, T. Nieusma, P. S. Lee, A. B. Ward, I. A.
Wilson, A. Dagley, D. F. Smee, D. Baker, D. H. Fuller, A Computationally Designed Hemagglutinin Stem-Binding Protein
Provides In Vivo Protection from Influenza Independent of a Host Immune Response. â€‹PLoS Pathog. â€‹ â€‹12, e1005409 (2016).
D. K. W. Chu, Y. Pan, S. M. S. Cheng, K. P. Y. Hui, P. Krishnan, Y. Liu, D. Y. M. Ng, C. K. C. Wan, P. Yang, Q. Wang, M.
Peiris, L. L. M. Poon, Molecular Diagnosis of a Novel Coronavirus (2019-nCoV) Causing an Outbreak of Pneumonia. â€‹Clin.
Chem.â€‹ â€‹66, 549â€“555 (2020).
P. Virtanen, R. Gommers, T. E. Oliphant, M. Haberland, T. Reddy, D. Cournapeau, E. Burovski, P. Peterson, W. Weckesser, J.
Bright, S. J. van der Walt, M. Brett, J. Wilson, K. J. Millman, N. Mayorov, A. R. J. Nelson, E. Jones, R. Kern, E. Larson, C. J.
Carey, Ä°. Polat, Y. Feng, E. W. Moore, J. VanderPlas, D. Laxalde, J. Perktold, R. Cimrman, I. Henriksen, E. A. Quintero, C. R.
Harris, A. M. Archibald, A. H. Ribeiro, F. Pedregosa, P. van Mulbregt, SciPy 1.0 Contributors, SciPy 1.0: fundamental algorithms
for scientific computing in Python. â€‹Nat. Methods.â€‹ â€‹17, 261â€“272 (2020).

Acknowledgments: The authors thank Michael Dougan, Leslie Aberman, Umut Ulge,
Julie Rathbun, and Jonathan Drachman, for useful discussions and comments on this
manuscript; Neoleukin Therapeutics, Inc. (â€œNeoleukinâ€) for supporting this work. All the
computational resources for the â€‹de novo protein design were provided by Neoleukinâ€™s
high-performance â€œNeoâ€ computational cluster. NIH grants AI145296 and AI127463 to
M.G.Jr.; â€‹HHSN272201400006C from NIAID, NIH to H.-L.Y and R01AI108197 to RSBâ€‹.
Neoleukinâ„¢ is a trademark of Neoleukin. The views and opinions expressed in this
article are those of the authors and do not necessarily reflect the position of Neoleukin.
Author Contributions: T.W.L. designed and coordinated the research, developed
computational design methods, designed de novo protein decoys of ACE2,
characterized designs, and wrote the manuscript; R.V. designed â€‹de novo proteins,
performed molecular biology, characterized and optimized the designs, and wrote the
manuscript; N.C. designed â€‹de novo proteins, characterized and optimized the designs,
and wrote the manuscript; J.W.N. designed de novo proteins, characterized and
optimized the designs, performed molecular biology, performed SSM experiments, and
wrote the manuscript; M.J.W. designed de novo proteins, performed molecular biology,
characterized and optimized the designs, and wrote the manuscript; W.S. performed
cell-neutralization assays with the live SARS-CoV-2 virus in Vero E6 cells and edited
8

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.03.231340; this version posted August 3, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Neoleukin Therapeutics, USA. 2020.

the manuscript; T.-Y.H. performed cell-neutralization assays with the live SARS-CoV-2
NanoLuc virus in Calu-3 cells; K.E.-N. performed cell-neutralization assays with the live
SARS-CoV-2 NanoLuc virus in Calu-3 cells; YJH developed the nLUC reporter virus;
K.Y. designed and performed ACE2 competition assays and developed methods to
quantify the â€‹de novo designs in tissue lysates; T.P. designed â€‹de novo proteins and
purified and characterized the â€‹de novo proteins; M.M. designed â€‹de novo proteins; A.P.
designed â€‹de novo proteins and performed binding characterizations; U.Y.L. designed â€‹de
novo proteins; M.Ma. performed pharmacokinetic studies in mice; J.C. performed
pharmacokinetic studies in mice;
A.C. performed ACE2 enzymatic assay and
cytotoxicity assays with VeroE6; T.B. purified and characterized the â€‹de novo proteins;
H.P. performed mass spectrometry; N.S.C. performed molecular biology; J.Ca.
developed and implemented computational tools for collaborative â€‹de novo protein
design; Y.-R.L. designed â€‹de novo proteins; A.J.-D. coordinated project operations and
wrote the manuscript; RSB coordinated the development of the nLUC reporter virus and
edited the paper; C.D.W. coordinated the research for ACE2 competition assays and
methods to quantify the â€‹de novo designs and edited the paper; R.S. coordinated the
research for in vitro neutralization testing and in vivo pharmacokinetics of the â€‹de novo
proteins and edited the paper; M.G.Jr. coordinated and directed the research for in vitro
NanoLuc SARS-CoV-2 neutralization and edited the paper; L.M.B.-M. designed â€‹de novo
proteins, coordinated the purification and characterization of the â€‹de novo proteins and
edited the paper; H.-L.Y. coordinated the research for in vitro SARS-CoV-2
neutralization and edited the paper; D.-A.S. generated the original idea to design the â€‹de
novo decoys to neutralize SARS-CoV-2, designed the research, developed
computational design selection strategies, wrote the manuscript, and directed the effort.
Competing Interests: T.W.L., N.C., J.W.N., and D.S. are inventors on provisional
patent applications for the de novo decoys described in this work. C.W and D.-A.S. are
co-founders and shareholders of Neoleukin Therapeutics.

9

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.03.231340; this version posted August 3, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Neoleukin Therapeutics, USA. 2020.

Figure legends:

Figure 1. Design and characterization of de novo ACE2 decoys. A) ACE2 (gray) and its binding motifs (H1 19-52, orange; H2
55-84, green; EE3 346-360, blue) to SARS-CoV-2 RBD (pink). Three starting structures were simultaneously used as the target (see
main text), 6VW1 is shown; â€‹B) Strategies for supporting the binding motifs. â€‹De novo secondary structure elements (magenta) were
computationally generated to stabilize H1, H2, and EE3. Seven combinations of secondary structure elements were considered.
Circles indicate Î±-helices, triangles indicate ð›½-sheets; filled circles are helices oriented forward and empty circles are the opposite.
We used Rosetta to generate fully connected backbones (â€œprotein_mimic_designerâ€ algorithm) and amino acid sequences predicted
to fold into the target structure. In all cases, the binding interface of ACE2 with the SARS-CoV-2 RBD was preserved intact (see
methods); â€‹C) Automatic computational filtering based on 8 metrics to select the best candidates. In addition, the RMSD of the
binding motifs to ACE2 was also used as a quality check. The dots indicate the mean computational score for each design scored
against the three target RBD structures. Designs selected for experimental testing are shown in black. Our best design, CTC-445, is
shown in red. The blue boxes indicate the filtering thresholds (see methods); â€‹D) Designs that passed filtering were subjected to
biased forward folding simulations (see methods), here shown for CTC-445, including the unsalted biased simulation (brown), the
native-salted (orange), and relaxation (blue). E) The top 196 designs were selected for yeast display screening using a combination
of Rosetta score per residue, ddG, and the folding simulations (see methods); The designs were individually assessed for specific
binding to SARS-CoV-2 spike RBD (Fc fusion, 200 nM). The plot for CTC-445 is shown. â€‹F) CTC-445 was recombinantly expressed
and purified by affinity chromatography (see methods). Analytical size exclusion chromatography (SEC) for CTC-445 revealed the
presence of oligomeric species; G) CTC-445 was optimized by directed evolution and rational combination of the observed favorable
mutations, leading to â€‹H) CTC-445.2 (SEC) which is mainly monomeric in solution and ~1000x more potent to compete ACE2 than its
parent (see â€œGâ€); we further optimized the potency of our molecule by generating a bivalent version named CTC-445.2d; â€‹I) Potency
of designs to outcompete binding of SARS-CoV-2 to ACE2, as measured by competition ELISA assays using a constant
concentration of 0.4 nM ACE2. J) Timeline of the de novo protein design and optimization pipeline. Timewise, a green color
indicates phases that we believe were carried out optimally, red can potentially be avoided in future efforts, and yellow are phases
that can potentially be expedited by using more advanced/automated methods for gene synthesis, cloning and high-throughput
screening.

10

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.03.231340; this version posted August 3, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Neoleukin Therapeutics, USA. 2020.

Figure 2. Binding, stability and structure of the de novo protein decoys CTC-445, CTC-445.2 and CTC-445.2d. A)
Computational models of CTC-445.2. Left, comparison of the SARS-CoV-2 binding interface surface of CTC-445.2 (top) and hACE2
(bottom). CTC-445.2 is designed to present the same binding interface as the one that SARS-CoV-2 targets in hACE2, down to the
level of individual interactions. Residues from the binding motifs: H1 are shown in shades of orange, residues from H2 in shades of
green and residues from EE3 in shades of blue. The boxes show detailed structural comparison of the interfaces between
CTC-445.2 and hACE2 with SARS-CoV-2 RBD. The relaxed complex of hACE2 with SARS-CoV-2 RBD (dark and light gray,
respectively; PDB: 6M17) are aligned to the model of the relaxed compex of CTC-445.2 and SARS-CoV-2 RBD (pink). Hydrogen
bond interactions are indicated by black dashed lines; â€‹B) Design models of CTC-445, CTC-445.2 and CTC-445.2d. CTC-445.2
contains 5 mutations that were guided by directed evolution experiments. CTC-445.2d is a bivalent variant composed of two
CTC-445.2 subunits linked by a 17-mer flexible GS linker (sequence -GGGGSGGSGSGGSGGGS-); â€‹C) Circular dichroism of
recombinantly expressed CTC-445 (red), CTC-445.2 (blue) and CTC-445.2d (orange). Thermally-induced meltings of the decoys
were followed by its circular dichroism signal at 208 nm (heating rate 2Â°C/min). The inset shows far UV wavelength spectra at 20 Â°C
(purple), after heating to ~95 Â°C (brown) and after cooling the heated sample to 20 Â°C (green dashed). Complete ellipticity-spectra
recovery (full reversibility) upon cooling was observed in all cases. Calculated Tâ€‹m values for CTC-445, CTC-445.2 and 445.2d are
75.3 Â± 0.2 Â°C, â‰ˆ93 Â°C and 71.7.Â± 0.2 Â°C; D) Chemical denaturation of CTC-445, CTC-445.2 and CTC-445.2d by incubation with
guanidine hydrochloride (0-6 M). Calculated values of Î”Gâ€‹ND, Î”Gâ€‹NI and Î”Gâ€‹ID were -9.8 Â± 0.8, -2.7 Â± 1.1 and -7.1 Â± 0.7 kcal molâ€‹-1 for
CTC-445, -14.6 Â± 2.0, -5.0 Â± 2.8 and -9.6 Â± 2.0 kcal molâ€‹-1 for CTC-445.2, and -19.0 Â± 1.7, -4.4 Â± 2.3 and -14.6 Â± 1.6 kcal molâ€‹-1 for
CTC-445.2d; â€‹E) Thermal recovery of CTC-445, CTC-445.2 and CTC-445.2d. Similar values of BCM were observed before and after
repeated cycles of heating and cooling for the three proteins; F) Octet binding assays of CTC-445, CTC-445.2 (left) and CTC-445.2d
(right) against immobilized SARS-CoV-2 RBD (top) and SARS-CoV-1 RBD (bottom). The RBD was immobilized to Anti-Penta-HIS
(HIS1K, ForteBio) and incubated with varying concentrations of ACE2 decoys. Binding kinetics were monitored by dipping the
biosensors in wells containing defined concentrations (4.7-300 nM for binding to SARS-CoV-2 and 30-2500 nM for binding to
SARS-CoV-1) of CTC-445, CTC-445.2, CTC-445.2d (association) and then dipping the sensors back into baseline wells
(dissociation). Data traces shown are a 2 s (10 data point) rolling average. Data for CTC-445 was fit to 1:1 model. For CTC-445 and
CTC-445.2, the results were globally fit using a 1:1 binding model (Kâ€‹dâ€‹=646 and 30 nM, kâ€‹onâ€‹=8.6 x 10â€‹4 and 3.9 x 10â€‹5 Mâ€‹-1â€‹sâ€‹-1â€‹, kâ€‹off =5.5 x
10â€‹-2 and 1.2 x 10â€‹-2 sâ€‹-1â€‹) and . For CTC-445.2d, the results were globally fit using a 2:1 binding model (Kâ€‹d â‰¤7.0 nM, kâ€‹onâ€‹=3.0 x 10â€‹5 Mâ€‹-1â€‹sâ€‹-1â€‹,
koffâ€‹â‰¤2.0 x 10-3 s-1).

11

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.03.231340; this version posted August 3, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Neoleukin Therapeutics, USA. 2020.

Figure 3. In vitro virus neutralization by CTC-445.2 and CTC-445.2d. CTC-445.2 (blue) and CTC-445.2d (orange) are shown. A)
SARS-CoV-2/VSV-Luc pseudovirus assay. Neutralization assays (left) were performed using a non-replicative VSV pseudovirus
carrying a luciferase reporter gene and expressing the spike protein of SARS-CoV-2 on its surface. Viral neutralization was
performed on HEK 293T cells overexpressing ACE2. The de novo decoys were pre-incubated with pseudovirus prior to incubation
with cells. Samples were tested in duplicate utilizing 3-fold serial dilutions started at 20 Î¼M (CTC-445.2) or 10 Î¼M (CTC-445.2d). A
cell viability assay (right) confirmed that the decoys are not cytotoxic to HEK 293T. We used an analogous pseudovirus expressing
an unrelated RBD to confirm that their neutralizing activity of the de novo decoys is specific (figure S11); â€‹B) (left) Neutralization of
NanoLuc SARS-CoV-2 by CTC-445 and CTC-445.2 in Calu-3 cells after a 72 h incubation; (right) A cell viability assay (48 h)
confirmed that the decoys are not cytotoxic to Calu-3; C) Neutralization of live BetaCoV/Hong Kong/VM20001061/2020
SARS-CoV-2 virus in Vero E6 cells. The cells were incubated with virus at both MOI 1.0 and MOI 0.01 throughout infection
(pre-incubated with virus, during infection, and post infection) (upper left), post-infection (upper right) and pre-infection only (lower
left). Cell viability in Vero E6 cells (lower right) was independently performed (CCK8 assay) and confirmed that the de novo decoys
are not cytotoxic. SARS-CoV-2 RNA copy numbers were determined by quantitative real-time RT-PCR. All assays were performed
in triplicate unless otherwise noted; â€‹D) Bioavailability of CTC-445.2d in mice lung (top) and plasma (bottom) after intranasal
administration (see methods); â€‹E) ACE2 functional activity as measured by enzymatic release of a free fluorophore from
Mca-APK(DNP) substrate. The de novo decoys didnâ€™t affect ACE2 function. DX600 was used as positive control (see methods).

12

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.03.231340; this version posted August 3, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Neoleukin Therapeutics, USA. 2020.

List of supplementary materials
1. Materials and methods
2. Table S1-S3
Table S1. SARS-CoV-2 neutralization by CTC-445.2 and CTC-445.2d in a
time-of-addition experiment.
Table S2. Characterization of recombinant, purified CTC-445 variants.
Table S3. Binding kinetics of de novo designed decoys with S protein RBDs.
3. Supplementary figures S1-S12:
Figure S1. Target mechanism of inhibition of SARS-CoV-2 by the de novo
designed ACE2 decoys.
Figure S2. Three dimensional structures of ACE2 in-complex with SARS-CoV-1
and SARS-CoV-2 RBD.
Figure S3. Yeast display characterization of CTC-445 binding to SARS-CoV-2
RBD and SARS-CoV-1 RBD.
Figure S4. Sequence alignment for the directed evolution of CTC-445 using
error-prone PCR and yeast display FACS.
Figure S5. Potency of CTC-445 variants â€‹v.s.â€‹ its molecular weight.
Figure S6. Mass spectrometry of CTC-445.2 and CTC-445.2d.
Figure S7. SEC-MALS of de novo designed decoys CTC-445, CTC-445.2 and
CTC-445.2d.
Figure S8. Thermal stability of hACE2.
Figure S9. Binding kinetics of CTC-445.2 and CTC-445.2d to SARS-CoV-1 RBD.
Figure S10. Kinetics of binding for CTC-445.2 to SARS-CoV-2 RBD mutants.
Figure S11. Inhibition of infection by VSV-Luc pseudovirus expressing VSVg.
Figure S12. Inhibition of SARS-CoV-2 (cytopathic effect) in Vero E6 cells.
Figure S13. CTC-445.3d, a further optimized CTC-445.2d variant. Stability,
thermal kinetics, binding and in vitro neutralization.
Figure S14. Yeast-display single-site saturation mutagenesis (SSM) library of the
SARS-CoV-2 RBD binding interface, effect on binding of CTC-445.2 and hACE2.

13

